Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Market Closed 04-02 16:00:00 EDT

71.03

-0.76

-1.05%

High71.95	Low70.47	Vol719.02M
Open71.76	D1 Closing71.78	Amplitude2.07%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O13.70B	T/O Rate--	Tradable Shares0.00
P/B6.882345	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":71.0267,"timestamp":1775159999999,"preClose":71.78392,"halted":0,"volume":719016511,"delay":0,"changeRate":-0.010549,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.757217,"latestTime":"04-02 16:00:00 EDT","open":71.756836,"high":71.95193,"low":70.46757,"amount":13696400934.289886,"amplitude":0.020678,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.882345,"peRate":-213.862339,"turnoverRate":0.021022,"increases":274,"decrements":223,"flats":19,"marketCap":1834472522951.625,"floatMarketCap":1636744247759.7656},"requestUrl":"/m/hq/s/BK4139/wiki","defaultTab":"wiki","newsList":[{"id":"2625461376","title":"A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2625461376","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625461376?lang=en_us&edition=fundamental","pubTime":"2026-04-04 23:21","pubTimestamp":1775316100,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) stock has been in focus after the FDA approved an expanded use of IMCIVREE for acquired hypothalamic obesity in patients as young as four. This decision broadens its treated population.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThe latest FDA approval, the positive European opinion on IMCIVREE and recent board changes have come alongside a 7 day share price return of 13.81%, while the 90 day share price return of 17.83% and very large 3 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/a-look-at-rhythm-pharmaceuticals-rytm-valuation-after-imcivr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/a-look-at-rhythm-pharmaceuticals-rytm-valuation-after-imcivr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","RYTM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625799613","title":"Incyte (INCY) Is Up 6.2% After Positive 54-Week HS and IO Combo Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2625799613","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625799613?lang=en_us&edition=fundamental","pubTime":"2026-04-04 23:16","pubTimestamp":1775315783,"startTime":"0","endTime":"0","summary":"In late March 2026, Incyte reported 54-week Phase 3 STOP-HS data showing durable efficacy and a consistent safety profile for its oral JAK1 inhibitor povorcitinib in adults with moderate to severe hidradenitis suppurativa. \nSeparately, Adagene recently announced a clinical collaboration under which Incyte will run a Phase 1 trial combining its TGFßR2 × PD-1 bispecific antibody INCA33890 with Adagene’s muzastotug in hard-to-treat microsatellite stable colorectal cancer, underscoring Incyte’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/incyte-incy-is-up-62-after-positive-54-week-hs-and-io-combo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/incyte-incy-is-up-62-after-positive-54-week-hs-and-io-combo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","INCY","BK4550","BK4588","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624023618","title":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624023618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624023618?lang=en_us&edition=fundamental","pubTime":"2026-04-04 22:50","pubTimestamp":1775314206,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and Anapty...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neumora-therapeutics-inc-nmra-palisade-bio-pali-and-anaptysbio-anab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neumora-therapeutics-inc-nmra-palisade-bio-pali-and-anaptysbio-anab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","PALI","BK4588","BK4137","ANAB","LABU","NMRA","BK4581","LU0029874061.USD","XLV","BK4585","HCSG","XBI","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625561327","title":"Assessing BioNTech (NasdaqGS:BNTX) Valuation After Analyst Moves And COVID Vaccine Trial Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2625561327","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625561327?lang=en_us&edition=fundamental","pubTime":"2026-04-04 22:17","pubTimestamp":1775312245,"startTime":"0","endTime":"0","summary":"Analyst reactions and trial setback keep focus on BioNTech (NasdaqGS:BNTX)\nRecent analyst actions, a CEO transition, softer COVID guidance, and the halt of recruitment in a major US COVID-19 vaccine trial have kept investor attention squarely on BioNTech (NasdaqGS:BNTX).\nSee our latest analysis for BioNTech.\nRecent price action reflects that tension, with a 6.42% 7 day share price return and a 1.97% move higher in the latest session coming after a 10.56% 1 month share price decline and a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-analyst-move","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bntx/biontech/news/assessing-biontech-nasdaqgsbntx-valuation-after-analyst-move","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BNTX","BK4568","BK4548","BK4585","BK4588","BK4535","BK4551","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624069038","title":"Assessing Disc Medicine (IRON) Valuation After FDA Complete Response Letter And Shareholder Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624069038","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624069038?lang=en_us&edition=fundamental","pubTime":"2026-04-04 19:22","pubTimestamp":1775301764,"startTime":"0","endTime":"0","summary":"Disc Medicine (IRON) is back in focus after the FDA issued a Complete Response Letter for its bitopertin program, triggering a 22% one day share price drop and a shareholder rights investigation.\nSee our latest analysis for Disc Medicine.\nBeyond the sharp reaction to the FDA Complete Response Letter and the shareholder rights investigation, Disc Medicine’s recent 7 day share price return of 8.47% and 30 day share price return of 8.02% sit alongside a 90 day share price return of 17.59% and a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/assessing-disc-medicine-iron-valuation-after-fda-complete-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/assessing-disc-medicine-iron-valuation-after-fda-complete-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4588","LU0053671581.USD","DCF","BK4585","BK4139","IRON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624694383","title":"Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624694383","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624694383?lang=en_us&edition=fundamental","pubTime":"2026-04-04 15:17","pubTimestamp":1775287059,"startTime":"0","endTime":"0","summary":"In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint.\nThe brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab.\nWe’ll now examine how the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-68-after-mixed-autoimmune-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","BK4543","BK4588","BK4023","BK4587","BK4528","BK4585","CHAT","ROIV","AGIX","AIPO","BK4139","BK4551","AIYY","AI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624999326","title":"Qyuns Therapeutics Co., Ltd. Class H (2509) Gets a Buy from CICC","url":"https://stock-news.laohu8.com/highlight/detail?id=2624999326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624999326?lang=en_us&edition=fundamental","pubTime":"2026-04-04 13:55","pubTimestamp":1775282137,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from CICC maintained a Buy rating on Qyuns Therapeutics Co., Ltd. Class H, with a price target of HK$33.00. The wor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/qyuns-therapeutics-co-ltd-class-h-2509-gets-a-buy-from-cicc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/qyuns-therapeutics-co-ltd-class-h-2509-gets-a-buy-from-cicc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","CICC","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624695008","title":"Assessing Ocugen (OCGN) Valuation After Strong One Year Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2624695008","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624695008?lang=en_us&edition=fundamental","pubTime":"2026-04-04 11:39","pubTimestamp":1775273975,"startTime":"0","endTime":"0","summary":"Ocugen’s recent performance and business profile\nOcugen (OCGN) has drawn fresh attention after recent price moves, prompting a closer look at how its current share level around US$1.79 relates to its business profile and recent return history.\nOver the past month, the stock shows a return of about 3%, while the past 3 months reflect a gain of about 30%. Over 1 year, the total return is reported at about 170%, and over 3 years about 130%. This contrasts with a 5 year total return that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-strong-one-year-share","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocgn/ocugen/news/assessing-ocugen-ocgn-valuation-after-strong-one-year-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4563","BK4139","BK4568","OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624693140","title":"Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624693140","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624693140?lang=en_us&edition=fundamental","pubTime":"2026-04-04 10:02","pubTimestamp":1775268179,"startTime":"0","endTime":"0","summary":"New insider activity at Annovis Bio ( ($ANVS) ) has taken place on April 3, 2026. Director Michael B. Hoffman has significantly increased his stake...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-insider-makes-bold-multi-million-dollar-move-into-annovis-bio-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669368","title":"Top Executive at Voyager Therapeutics Makes Notable Stock Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669368","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669368?lang=en_us&edition=fundamental","pubTime":"2026-04-04 10:02","pubTimestamp":1775268123,"startTime":"0","endTime":"0","summary":"New insider activity at Voyager Therapeutics ( ($VYGR) ) has taken place on April 3, 2026. Voyager Therapeutics has seen insider activity as Presid...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-at-voyager-therapeutics-makes-notable-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-at-voyager-therapeutics-makes-notable-stock-move-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698202","title":"Spyre CEO Cameron Turtle disposes of $0.7 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698202?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:31","pubTimestamp":1775266278,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO Turtle Cameron sold 15,000 shares on April 1.Sales totaled about 0.7 million at weighted average prices of $49.2 and $49.92.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL7Znhxy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698274","title":"Spyre Therapeutics CMO Sheldon Sloan disposes of common shares worth 0.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698274","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698274?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266244,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Chief Medical Officer Sheldon Sloan reported sale of 7,958 shares on April 1, 2026 at USD 50.Transaction followed exercise of stock options for 7,958 shares at USD 21.66.Sloan reported 0 shares of common stock owned following transactions.Filing showed 87,542 stock options held following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL92MLgv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CMO Sheldon Sloan disposes of common shares worth 0.4 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624982086","title":"Spyre CFO Scott Burrows disposes Spyre Therapeutics common stock worth $369,004.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2624982086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624982086?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266207,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CFO Scott L Burrows cut direct holdings to 97,994 shares in transactions dated April 1, 2026.Burrows sold 7,500 shares at USD 49.21 to USD 49.98 per share.He acquired 7,500 shares at USD 14.5 per share through an option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL162p2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624669875","title":"The Trader: Biotechs Are a Healthy Growth Bet. Thank M&A and New Drugs. -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2624669875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624669875?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:30","pubTimestamp":1775266200,"startTime":"0","endTime":"0","summary":"Big Pharma companies are constantly searching for the next hot new drugs -- and it's often a lot easier to buy them than develop them. That's great news for biotech investors. Merger activity is starting to heat up again in the sector.There were three notable deals in March alone. Biogen just announced a deal to buy Apellis Pharmaceuticals, a developer of immunological and rare-disease medications, for $5.6 billion, a takeover premium of nearly 140%. Mounjaro owner Eli Lilly is buying sleep-drug maker Centessa Pharmaceuticals for $7.8 billion. And Merck said it would buy Terns Pharmaceuticals, which is working on a drug to treat leukemia, for $6.7 billion.Mergers won't be the only catalyst for biotechs. Analysts at Cantor Fitzgerald pointed out in a report in March that they expect about 80% of the companies in the State Street SPDR S&P Biotech ETF will have approved drugs by the third quarter of next year. This, according to Cantor, suggests the industry is \"still early in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU0889565916.HKD","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU1983260115.SGD","ARGX","BK4135","IE00BJT1NW94.SGD","IE00BGHQF748.EUR","STT","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1093756325.SGD","LU0061475181.USD","LU1093756168.USD","APLS","TERN","IE0002141913.USD","LU1894683264.USD","LU1883839398.USD","CNTA","BK4539","IE0034235188.USD","IE00BJJMRZ35.SGD","KALV","BK4535","BK4588","LU0320765992.SGD","LU1894683348.USD","IE0009355771.USD","BK4585","LU2324357040.USD","LU0109394709.USD","BK4007","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698903","title":"Natera President Clinical Diagnostics Solomon Moshkevich disposes shares worth $0.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698903","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698903?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:05","pubTimestamp":1775264755,"startTime":"0","endTime":"0","summary":"Natera President, Clinical Diagnostics Solomon Moshkevich sold 3,000 common shares on April 1, 2026.Sale prices averaged about USD 201.32 to USD 203.31 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDLVmmKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU2065731478.USD","NTRA","LU1064131342.USD","LU2065170008.USD","LU2324357040.USD","LU2065171402.SGD","LU0345770308.USD","LU0345770993.USD","LU1988902786.USD","LU0012050646.USD","LU2065171311.SGD","LU0053671581.USD","BK4139","LU2264538146.SGD","LU0106261612.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624698905","title":"Natera Chief Legal Officer Daniel Rabinowitz disposes of USD 1.7 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624698905","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624698905?lang=en_us&edition=fundamental","pubTime":"2026-04-04 09:05","pubTimestamp":1775264753,"startTime":"0","endTime":"0","summary":"Natera Secretary and Chief Legal Officer Daniel Rabinowitz sold 8,400 shares on April 1, 2026.Sales were executed at weighted average prices ranging from $200.79 to $205.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL6CpxR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Chief Legal Officer Daniel Rabinowitz disposes of USD 1.7 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU2065731478.USD","LU2065171402.SGD","NTRA","LU0963586101.USD","LU2065171311.SGD","LU2324357040.USD","LU0106261612.USD","LU1064131342.USD","LU0345770308.USD","LU2065170008.USD","LU0053671581.USD","BK4139","LU2065169927.USD","LU0012050646.USD","LU1988902786.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624660415","title":"Innate Pharma Balances Pipeline Progress With Cash Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=2624660415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624660415?lang=en_us&edition=fundamental","pubTime":"2026-04-04 08:07","pubTimestamp":1775261223,"startTime":"0","endTime":"0","summary":"Innate Pharma S.A. (($FR:IPH)) has held its Q4 earnings call. Read on for the main highlights of the call. Innate Pharma’s latest earnings call str...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-balances-pipeline-progress-with-cash-strain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-balances-pipeline-progress-with-cash-strain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","LU2065732104.USD","PRGS","BK4097","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624660557","title":"Apogee CMO Carl Dambkowski disposes of USD 0.5 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624660557","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624660557?lang=en_us&edition=fundamental","pubTime":"2026-04-04 08:01","pubTimestamp":1775260888,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised stock options for 4,125 shares on April 1, 2026 at USD 22.86 per share.Dambkowski sold 5,500 shares on April 1, 2026 at weighted average prices of USD 84.31 and USD 85.33 per share.Directly held common stock position ended day at 208,398 shares.Stock options beneficially owned fell to 127,165 shares following exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL2BZbTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624266055","title":"Apogee CFO Jane Henderson disposes of $0.2 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624266055","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624266055?lang=en_us&edition=fundamental","pubTime":"2026-04-04 08:00","pubTimestamp":1775260852,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics CFO Jane Henderson reported sale of 2,000 common shares on April 1, 2026.Shares sold at weighted average prices of $84.46, $85.46.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260404:nNDL5cSj0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee CFO Jane Henderson disposes of $0.2 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624608586","title":"Immunome CSO Jack Higgins disposes of $0.2 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624608586","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624608586?lang=en_us&edition=fundamental","pubTime":"2026-04-04 07:48","pubTimestamp":1775260135,"startTime":"0","endTime":"0","summary":"Immunome Chief Scientific Officer Jack Higgins sold 9,438 shares on April 2, 2026 at $21.64.Directly held stake fell to 22,000 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL93B6bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","IMNM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction